Literature DB >> 10561523

Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data.

Y Ihara1, M Chuda, S Kuroda, T Hayabara.   

Abstract

Hydroxyl radical (.OH) levels in blood, superoxide dismutase (SOD) activity in plasma (plasma-SOD) and in red blood cells (RBC) relative to Cu,Zn-SOD (SOD1) protein (RBC-SOD/SOD1), SOD1 protein in RBC (SOD1/RBC) and plasma (SOD1/plasma), and Mn-SOD protein in plasma (SOD2/plasma) were measured in patients with Parkinson's disease (PD), multiple-system atrophy (MSA) with parkinsonism, and in control subjects. Patients with PD had significantly higher.OH and plasma-SOD values and significantly lower RBC-SOD/SOD1 and SOD1/RBC values than the corresponding MSA and control values. In PD, RBC-SOD/SOD1 values were significantly lower in older patients and were negatively correlated with age.OH levels were significantly higher in PD patients with early onset, a long period of illness or severe Yahr stage, and were negatively correlated with onset and positively correlated with duration of illness. RBC-SOD/SOD1 values in PD patients who received pergolide therapy were significantly higher than those in PD patients who received neither pergolide nor bromocriptine therapy. Therefore, the higher.OH level and the lower SOD1 activity may play a role in the onset and progression of PD, and pergolide may act neuroprotectively by inducing SOD1 activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561523     DOI: 10.1016/s0022-510x(99)00192-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  21 in total

Review 1.  Synthetic analogues of cysteinate-ligated non-heme iron and non-corrinoid cobalt enzymes.

Authors:  Julie A Kovacs
Journal:  Chem Rev       Date:  2004-02       Impact factor: 60.622

Review 2.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

3.  Copper chaperone for Cu,Zn-SOD supplement potentiates the Cu,Zn-SOD function of neuroprotective effects against ischemic neuronal damage in the gerbil hippocampus.

Authors:  In Koo Hwang; Won Sik Eum; Ki-Yeon Yoo; Jun Hwi Cho; Dae Won Kim; Soo Hyun Choi; Tae-Cheon Kang; Oh-Shin Kwon; Jung Hoon Kang; Soo Young Choi; Moo Ho Won
Journal:  Free Radic Biol Med       Date:  2005-04-13       Impact factor: 7.376

Review 4.  Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.

Authors:  Anubhuti Dixit; Rachna Mehta; Abhishek Kumar Singh
Journal:  Cell Mol Neurobiol       Date:  2019-06-12       Impact factor: 5.046

5.  Superoxide Oxidation by a Thiolate-Ligated Iron Complex and Anion Inhibition.

Authors:  Maksym A Dedushko; Jessica H Pikul; Julie A Kovacs
Journal:  Inorg Chem       Date:  2021-04-26       Impact factor: 5.165

6.  Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease.

Authors:  G Watfa; C Dragonas; T Brosche; R Dittrich; C C Sieber; C Alecu; A Benetos; R Nzietchueng
Journal:  J Nutr Health Aging       Date:  2011-04       Impact factor: 4.075

Review 7.  Biomarkers in Parkinson's disease.

Authors:  John C Morgan; Shyamal H Mehta; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2010-11       Impact factor: 5.081

8.  A functional model for the cysteinate-ligated non-heme iron enzyme superoxide reductase (SOR).

Authors:  Terutaka Kitagawa; Abhishek Dey; Priscilla Lugo-Mas; Jason B Benedict; Werner Kaminsky; Edward Solomon; Julie A Kovacs
Journal:  J Am Chem Soc       Date:  2006-11-15       Impact factor: 15.419

9.  Scavenging of reactive oxygen and nitrogen species with nanomaterials.

Authors:  Carolina A Ferreira; Dalong Ni; Zachary T Rosenkrans; Weibo Cai
Journal:  Nano Res       Date:  2018-05-26       Impact factor: 8.897

Review 10.  SOD2 in mitochondrial dysfunction and neurodegeneration.

Authors:  James M Flynn; Simon Melov
Journal:  Free Radic Biol Med       Date:  2013-05-29       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.